title: Prostate Cancer Screening and the Associated Controversy.
abstract: Prostate cancer is the most common malignancy diagnosed in men and the second leading cause of cancer death for men in the United States. Widespread use of prostate-specific antigen (PSA) screening led to a decrease in mortality; however, PSA screening may have led to overdiagnosis and overtreatment of clinically insignificant cancers. The US Preventive Services Task Force (USPSTF) released a statement recommending against the use of PSA, which was met with concern from professional organizations. This article reviews the epidemiology of prostate cancer, data from the largest screening trials, USPSTF recommendation statement, and current strategies used to improve overdiagnosis and overtreatment.
authors: Urology Institute, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
authors: William
authors: W
authors: Tabayoyong
authors: Urology Institute, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106, USA. Electronic address: Robert.Abouassaly@UHhospitals.org.
authors: Robert
authors: R
authors: Abouassaly
mesh_terms: D055088:Early Detection of Cancer / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000009:adverse effects / Q000379:methods; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D012307:Risk Factors; D014481:United States
chemical_list: D017430:Prostate-Specific Antigen
keywords: Prostate cancer; Prostate specific antigen; Screening